Korean biotech developing antibody-drug-conjugate (ADC) cancer therapies, spun out of Samsung Medical Center research.
Korean biotech developing antibody-drug-conjugate (ADC) cancer therapies, spun out of Samsung Medical Center research.
Cannot sell a drug yet, so income comes from licence fees: up-front and milestone payments from large drug companies that take rights to its technology, with royalties if a drug reaches the market. ADCs link an antibody that homes in on cancer cells to a toxic payload.
Moat: narrow (IP / patents). Proprietary ADC linker/payload technology validated by a large Boehringer Ingelheim licensing deal.
Headquarters: Seoul, South Korea · Founded: 2018
Size Aimed Bio (0009K0.KS) is a South Korea Industrials company (Miscellaneous Commercial Services) with a market value of $778M, the 277th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩15,930 on 18 Nov 2026.
Performance Over six months the shares fell 61.1%, against +7.7% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 228.2% over the last twelve months (peer median +5.2%); the operating margin is 34.4% (peer median 6.7%).
Valuation It trades at 13.8× enterprise value to sales against a peer median of 4.1× (5th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +652%, so the hurdle is -642 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.9 points above its cost of capital (5.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩67.9B | ₩47.3B | ₩11.8B | ₩171M | ₩111M |
| Revenue growth | — | +302% | +6,769% | +54% | — |
| Gross profit | ₩55.6B | ₩38.7B | ₩6.35B | -₩4.36B | -₩4.56B |
| EBITDA | ₩25.2B | ₩22.2B | ₩1.06B | -₩5.36B | -₩4.81B |
| Net income | ₩34.3B | ₩5.02B | -₩3.30B | -₩9.02B | -₩6.17B |
| Free cash flow | ₩23.9B | ₩17.5B | -₩5.10B | -₩3.44B | -₩4.36B |
| Capital expenditure | ₩1.89B | ₩363M | ₩1.68B | ₩796M | ₩521M |
| Total debt | ₩1.36B | ₩1.16B | ₩41.9B | ₩11.8B | ₩1.01B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Aimed Bio 0009K0.KS | $778M | -61% | +228% | 34% | 13.8× | 10.2% |
| ABL Bio 298380.KS | $1.51B | -71% | -53% | -201% | 46.5× | n/a |
| LigaChem Biosciences 141080.KS | $1.48B | -72% | -55% | -324% | 17.0× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 0009K0.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -29.4% | -4.2% | 2nd lowest of 21 |
| 6-month return | -61.1% | +7.7% | 2nd lowest of 21 |
| Distance from 52-week high | -80.1% | -25.4% | 2nd lowest of 21 |
| Revenue growth (TTM) | +228.2% | +5.2% | highest of 21 |
| Operating margin | 34.4% | 6.7% | 2nd highest of 21 |
| EV / Sales | 13.8× | 4.1× | 5th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 10.2% | 1.6% | 2nd most demanding of 11 |
| Growth delivered (Del g) | +652.2% | +8.5% | highest of 11 |
| Hurdle (Req g minus delivered) | -642.0 pp | -11.9 pp | least demanding of 11 |
| ROIC minus cost of capital | +10.9 pp | -3.1 pp | 3rd highest of 19 |
| EV / EBITDA | 37.2× | 8.7× | most expensive of 9 |
| Net debt / EBITDA | -3.8× | 0.9× | 2nd least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aimed Bio 0009K0.KS | South Korea | $778M | -61% | +228% | 34% | 13.8× | 10.2% | +652.2% |
| Anbang Save-Guard 603373.SS | China | $779M | +6% | -1% | 14% | 1.9× | 5.6% | +5.6% |
| Beyondsoft 002649.SZ | China | $769M | -14% | -6% | 2% | 0.6× | 7.0% | +9.2% |
| Daqian Ecology & Environment 603955.SS | China | $769M | +21% | +217% | -53% | 14.7× | n/a | n/a |
| Omat Advanced Materials (Guangdong) 688530.SS | China | $757M | -19% | +82% | 9% | 5.7× | n/a | n/a |
| Beijing Haitian Ruisheng Science Technology 688787.SS | China | $801M | -37% | +34% | 4% | 11.9× | n/a | n/a |
| BrightView BV | United States | $803M | -29% | +1% | 4% | 0.9× | n/a | n/a |
| Mentari Therapeutics MTRI | United States | $807M | -91% | -83% | -1,239% | 982.9× | n/a | n/a |
| IBEX IBEX | United States | $744M | +79% | +15% | 9% | 1.1× | 1.0% | +7.7% |
| transcosmos 9715.T | Japan | $814M | -11% | +6% | 4% | 0.2× | -18.2% | +3.2% |
| Funshine Culture 300860.SZ | China | $739M | 0% | -49% | -35% | 10.1× | 21.5% | -24.6% |
| Karnov KAR.ST | Sweden | $820M | +9% | -4% | 20% | 4.1× | 5.1% | +27.9% |
| Shandong Link Science and Technology 001207.SZ | China | $733M | -24% | +7% | 13% | 1.7× | -5.5% | +18.9% |
| TaskUs TASK | United States | $827M | +50% | +9% | 12% | 0.9× | 1.3% | +19.9% |
| Cuscal CCL.AX | Australia | $728M | +17% | +19% | 12% | n/a | n/a | n/a |
| Funai Soken 9757.T | Japan | $724M | +10% | +5% | 25% | 2.9× | -8.7% | +5.9% |
| Dark Horse Technology 300688.SZ | China | $723M | +12% | -32% | -33% | 41.7× | n/a | n/a |
| Shenzhen L&A Design 300949.SZ | China | $715M | +98% | 0% | -28% | 11.8× | n/a | n/a |
| Shaanxi Fenghuo Electronics 000561.SZ | China | $851M | -27% | +8% | -26% | 4.1× | n/a | n/a |
| Credit CCP.AX | Australia | $704M | +39% | +7% | 26% | 2.5× | 1.9% | +11.1% |
| IP Group plc IPO.L | United Kingdom | $865M | +11% | -37% | 51% | 15.5× | n/a | n/a |